HSP70 modified response against HPV based tumor

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 2, 2013, Pages 228-234

  Farzanehpour, M ^b   Soleimanjahi, H ^a   Hassan, Z M ^b   Amanzadeh, A ^b   Ghaemi, A ^b   Fazeli, M ^b  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

DNA vaccine; Enhancement; HPV16 E7; HSP70

Indexed keywords

CANCER VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN 70; PLASMID DNA; PROTEIN E7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; SKIN TUMOR; TUMOR CELL DESTRUCTION; TUMOR IMMUNITY; TUMOR VOLUME;

ANIMALS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VACCINATION; VACCINES, DNA;

EID: 84878615548     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. HUNG CF, MONIE A, ALVAREZ RD, WU TC. DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 2007; 39: 679-689.
2. BOSCH FX, MANOS MM, MUNOZ N, SHERMAN M, JANSEN AM, PETO J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
3. RAFATI S, NAKHAEE A, TAHERI T, TASLIMI Y, DARABI H, ERAVANI D, Sanos S, Kaye P, Tagshikhani M, Jamshidi S, Rad MA. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005; 23: 3716-3725.
4. PIECHOCKI MP, PILON SA, WEI WZ. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 2001; 167: 3367-3374.
5. WU TC. Immunology of the human papilloma virus in relation to cancer. Curr Opin Immunol 1994; 6: 746-754.
6. SANTIN AD, BELLONE S, ROMAN JJ, BURNETT A, CANNON MJ, PECORELLI S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des 2005; 11: 3485-3500.
7. MESHKAT Z, SOLEIMANJAHI H, MAHMOUDI M, MIRSHAHABI H, HASSAN ZM, GHAFFARI SR, et al. Determina- tion of human papillomavirus type 16 genotype and construction of cloning vector pTZ57R encoding HPV16 E7 gene. Saudi Med J 2007; 28: 1511-1515.
8. JAZAYERI M, SOLEIMANJAHI H, FOTOUHI F, PAKRAVAN N. Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice. Comp Immunol Microbiol Infect Dis 2009; 32: 453-461.
9. WATTS AM, KENNEDY RC. DNA vaccination strategies against infectious diseases. Int J Parasitol 1999; 29: 1149-1163.
10. GAMVRELLIS A, LEONG D, HANLEY JC, XIANG SD, MOTTRAM P, PLEBANSKI M. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol 2004; 82: 506-516.
11. YAN J, REICHENBACH DK, CORBITT N, HOKEY DA, RAMANATHAN MP, MCKINNEY KA, Weiner DB, Sewell D. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 2009; 27: 431-440.
12. FYNAN EF, WEBSTER RG, FULLER DH, HAYNES JR, SANTORO JC, ROBINSON HL. DNA vaccines: a novel approach to immunization. Int J Immunopharmacol 1995; 17: 79-83.
13. PAKRAVAN N, SOLEIMANJAHI H, HASSAN ZM. GP96 Cterminal improves Her2/neu DNA vaccine. J Gene Med 2010; 12: 345-353.
14. GURUNATHAN S, WU CY, FREIDAG BL, SEDER RA. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 2000; 12: 442-447.
15. MESHKAT Z, SOLEIMANJAHI H, MAHMOUDI M, HASSAN ZM, MIRSHAHABI H, MESHKAT M, Kheirandish M. CTL responses to a DNA vaccine encoding E7 gene of human papillomavirus type 16 from an Iranian isolate. Iran J Immunol 2008; 5: 82-91.
16. GHAEMI A, SOLEIMANJAHI H, GILL P, HASSAN ZM, RAZEGHI S, FAZELI M, Razavinikoo SM. Protection of mice by λ-based therapeutic vaccine against cancer associated with human papillomavirus type 16. Intervirology 2011; 54: 105-112.
17. PENG S, TRIMBLE C, ALVAREZ RD, HUH WK, LIN Z, MONIE A, Hung CF, Wu TC. Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Ther 2008; 15: 1156-1166.
18. MANJILI MH, WANG XY, PARK J, FACCIPONTE JG, REPASKY EA, SUBJECK JR. Immunotherapy of cancer using heat shock proteins. Curr Opin Mol Ther 2002; 9: 385-391.
19. BOLHASSANI A, GHOLAMI E, ZAHEDIFARD F, MORADIN N, PARSI P, DOUSTDARI F, SEYD N, PAPADOPOULOU B, RAFATI S. Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model. Exp Parasitol 2011; 128: 9-17.
20. FRYDMAN J. Folding of newly translated proteins in vivo: the role of molecular chaperones. Annu Rev Biochem 2001; 70: 603-647.
21. PANJWANI NN, POPOVA L, SRIVASTAVA PK. Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs. J Immunol 2002; 168: 2997-3003.
22. KHANNA R. Tumour surveillance: missing peptides and MHC molecules. Immunol Cell Biol 1998, 76: 20-26.